Figure 6.

C26 suppresses metastatic growth in lungs by inducing dormancy. (A) Lungs from DMSO- or C26-treated mice described in Fig. 4 were immunostained for vimentin, Ki-67, and NR2F1. Scale bar, 50 µm. (B and C) Graphs showing the percentage of Ki-67⁺/vimentin⁺ (B) or NR2F1⁺/vimentin⁺ (C) tumor cells in lungs. Data are mean ± SEM. (D) Graph showing box (25th to 75th percentile) and whiskers (minimum to maximum values) of nuclear NR2F1 MFI per cell. Data in B–D are from five mice per group (DMSO, 250 cells; C26, 150 cells). *, P < 0.05; **, P < 0.01; ****, P < 0.0001 by t test. (E) Lungs from DMSO- or C26-treated mice described in Fig. 4 were immunostained for vimentin and p27. Scale bar, 50 µm. (F) Graph showing the percentage of vimentin⁺ tumor cells with nuclear accumulation of p27. Data are mean ± SEM. (G) Graph shows box (25th to 75th percentile) and whiskers (minimum to maximum values) of nuclear p27 MFI per cell in vimentin⁺ tumor cells. Data in F and G are from five mice per group (DMSO, 174 cells; C26, 85 cells). **, P < 0.01; ****, P < 0.0001 by t test. (H) Lungs from DMSO- or C26-treated mice described in Fig. 4 were immunostained for vimentin and p-S6. Scale bar, 50 µm. Arrowheads in C26 indicate solitary DTCs that are negative for p-S6. (I) Graph showing the percentage of vimentin⁺ tumor cells with a positive p-S6 signal. Data are mean ± SEM from five mice per group. **, P < 0.01 by t test. See also Fig. S5.